Clinical Report: Assessment of eribulin's effectiveness in breast cancer patients
Overview
This retrospective analysis evaluated the efficacy and safety of eribulin in 73 breast cancer patients with liver metastases treated between 2020 and 2024. The study found a median progression-free survival of 3.7 months and an objective response rate of 15.1%, indicating preliminary activity of eribulin in this patient population.
Background
Breast cancer remains the most prevalent malignancy among women globally, with a significant proportion developing liver metastases, which are associated with poor prognosis. Current systemic therapies are crucial for managing metastatic breast cancer, particularly in patients with liver involvement, where treatment options are limited. Understanding the effectiveness of agents like eribulin in this context is essential for improving patient outcomes.
Data Highlights
Measure
Value
95% CI
Median Progression-Free Survival
3.7 months
2.8–4.6
Objective Response Rate
15.1%
7.8%–25.4%
Highest Objective Response Rate (HR+/HER2−)
21.2%
N/A
Neutropenia
42.5%
N/A
Fatigue
37.0%
N/A
Alopecia
34.2%
N/A
Peripheral Neuropathy
28.8%
N/A
Key Findings
Median progression-free survival with eribulin was 3.7 months.
Objective response rate was 15.1%, with partial responses only.
The highest response rate (21.2%) was observed in HR+/HER2− subtype patients.
Common adverse events included neutropenia (42.5%), fatigue (37.0%), alopecia (34.2%), and peripheral neuropathy (28.8%).
No treatment-related deaths were reported in the study.
Clinical Implications
Eribulin may provide a treatment option for heavily pre-treated breast cancer patients with liver metastases, although the response rates are modest. Clinicians should monitor for common adverse events, particularly neutropenia, alopecia, and peripheral neuropathy, when administering eribulin in this population.
Conclusion
This study suggests that eribulin has preliminary activity in breast cancer patients with liver metastases, warranting further prospective studies to validate these findings.
